Barrow Robert 4

What Happened Robert Barrow, CEO of Definium Therapeutics (DFTX), reported a sale of 29,208 common shares on June 25, 2026 at $45.03 per share, totaling $1,315,236. The transaction is reported as a sale (S) and was executed to satisfy tax withholding obligations associated with the settlement of vested restricted stock units (RSUs).

Key Details

• Transaction date: 2026-06-25
• Price per share: $45.03; Total value: $1,315,236
• Transaction type: Sale (S) — reported as open market/private sale
• Footnote: Sale used to satisfy withholding tax on vested RSUs pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted June 15, 2022 (Footnote F1)
• Shares owned after transaction: Not specified in the provided filing
• Filing date: 2026-06-26 (reported promptly; no late filing indicated)

Context Sell-to-cover transactions are routine when RSUs vest: a portion of shares is sold to cover tax withholding rather than representing a discretionary cash sale by the insider. Such sales are common and are not, by themselves, clear signals of the insider’s view on the company’s prospects.